Trials / Completed
CompletedNCT01722825
Study of LY2157299 in Japanese Participants With Cancer
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2157299 | Administered orally. |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2012-11-07
- Last updated
- 2014-07-01
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01722825. Inclusion in this directory is not an endorsement.